Moderna-Merck Vaccine Breakthrough Cuts Melanoma Recurrence by Almost Half

Moderna and Merck have announced a major breakthrough in cancer treatment. A personalized mRNA vaccine, when combined with Merck's Keytruda immunotherapy drug, reduced the risk of melanoma recurrence and spread by nearly half. The trial involved over 1,100 patients with high-risk stage IIB-IV melanoma.

The vaccine trains the patient's immune system to target specific mutations in tumor cells. This is a significant advancement in the field of cancer treatment, as it shows that adding another treatment to Keytruda can be more effective than using Keytruda alone. The results have sparked renewed interest in the biotechnology sector.

Moderna's stock surged by 160% after the announcement, increasing the company's market capitalization by nearly $40 billion. Merck's stock also rose by 12%. The trial has paved the way for further research into similar approaches for other types of cancer, such as lung and breast cancer.

Moderna President Stephen Hoge stated that 'this is the first time we have observed truly clinically and statistically significant improvements compared to immune-system inhibitors such as Keytruda in this group of patients, and this is the first time we have been able to achieve this through personalized treatment.'